GLP-1 physiology informs the pharmacotherapy of obesity

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-dependent insulin release and reduce glucagon secretion and gastric emptying, enabling their successful development for the treatment of type 2 diabetes (T2D). These agents also inhibit food intake and reduce body weight,...

Descripción completa

Detalles Bibliográficos
Autor principal: Drucker, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859548/
https://www.ncbi.nlm.nih.gov/pubmed/34626851
http://dx.doi.org/10.1016/j.molmet.2021.101351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859548/
https://www.ncbi.nlm.nih.gov/pubmed/34626851
http://dx.doi.org/10.1016/j.molmet.2021.101351

Ejemplares similares